Of interest in 2010: the Anthos 2010 microplate reader
Order before 30 June for free software upgrade
Four filters are supplied as standard that cover the wavelengths for most common absorbance assays with a colorimetric endpoint, e.g. ELISA, BCA, Bradford and Lowry assays, and additional filters are available.
A choice of software packages enables the user to connect to a PC and run both endpoint and kinetic assays with ease. Results can be printed directly or exported to a spreadsheet for further analysis.
Order the Biochrom Anthos 2010 instrument before the end of June 2010 and the user will receive a free software upgrade to program the plate layout with blanks, standards and controls. This permits the user to perform qualitative analysis on the results or quantify unknown samples using a standard curve eliminating outliers.
The Biochrom Anthos range of high performance microplate instrumentation is manufactured by Biochrom and available worldwide.
For complete specifications on the Biochrom Anthos microplate readers as well as the complete Biochrom product line go to www.Biochrom.co.uk
You may also like
Trending Articles
You may also like
Manufacturing
Lonza appoints Hans Trees as Global Head of Communications
Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Manufacturing
AlzeCure licenses Alzheimer’s candidate ACD680 to Lilly in deal worth up to $1bn
AlzeCure Pharma has entered a global licensing and collaboration agreement with Eli Lilly for its Alzheimer's disease candidate ACD680, securing a $10m upfront payment and potential milestone payments exceeding $1bn
Manufacturing
Safety in pharmaceutical manufacturing: why a trusted partner makes all the difference
By taking a three-tiered approach to protecting patients and personnel and ensuring plant compliance, GEA adopts a consultative approach to helping its customers navigate the responsibilities of pharmaceutical manufacturing safety with confidence
Manufacturing
Aragen to manufacture Renaissance Pharma’s FDA Fast Track mAb as part of ongoing strategic collaboration
CRDMO successfully scaled and transferred Renaissance Pharma’s lead candidate, Daretabart a humanised monoclonal antibody targeting GD2 for high-risk neuroblastoma, in just 9 months